
Supplied as sealed pharmaceutical-grade tablets in a 100-count bottle, verified for identity and potency before dispatch.
| Contents | 100 tablets, 100mg each |
| Form | Oral tablet |
| Storage | Cool and dry, away from light |
| Batch | Sealed bottle |
Supplied as sealed pharmaceutical-grade tablets in a 100-count bottle, verified for identity and potency before dispatch.
Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor and the first compound of its class to reach market. It blocks the enzyme that degrades cyclic guanosine monophosphate (cGMP), allowing that second messenger to accumulate and prolonging smooth muscle relaxation in vascular tissue.
It was originally investigated as an antianginal agent; the vascular effects observed during those trials redirected its development entirely — one of the better-documented cases of clinical repurposing in modern pharmacology.
Supplied as sealed pharmaceutical-grade tablets, 100-count, verified for identity and potency. Prescription medicine in most jurisdictions.
Sildenafil does not initiate the nitric oxide signalling cascade — it prevents the breakdown of cGMP once that cascade is already active. This dependence on existing NO signalling is why the pharmacology is described as permissive rather than initiating.
Onset is roughly 30 to 60 minutes with a half-life near 4 hours, considerably shorter than tadalafil. Absorption is affected by food, particularly high-fat meals, which is a documented pharmacokinetic interaction.
A separate and substantial literature concerns sildenafil in pulmonary arterial hypertension, where PDE5 inhibition in the pulmonary vasculature reduces pulmonary arterial pressure. It is approved for this indication under a different brand and strength.
Sildenafil is an approved prescription medicine with a large clinical evidence base. It should be obtained and used under medical supervision.
Supplied in sealed manufacturer packaging, verified for identity and labelled potency before dispatch.
Do not accept product with a broken seal.
Join the Peps Depot mailing list for high-demand restock alerts, subscriber-only offers, release updates and priority access — plus The Friday Brief, our weekly peptide research newsletter covering what actually moved that week. New compounds, new trial data, regulatory shifts.